MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

154.96
+2.42
+1.59%
Pre Market: 159.34 +4.38 +2.83% 09:11 01/27 EST
OPEN
157.99
PREV CLOSE
152.54
HIGH
165.85
LOW
152.80
VOLUME
29.49K
TURNOVER
--
52 WEEK HIGH
497.49
52 WEEK LOW
117.34
MARKET CAP
62.83B
P/E (TTM)
9.52
1D
5D
1M
3M
1Y
5Y
IAVI And Moderna Launch Trial Of HIV Vaccine Antigens Delivered Through mRNA Technology
Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company
Benzinga · 10m ago
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 1h ago
Coronavirus tally: Moderna starts to test an omicron-specific COVID vaccine booster in health adults
Moderna has begun testing an omicron-specific COVID-19 booster in healthy adults, following in the wake of a study announced earlier this week by Pfizer and German partner BioNTech ,the Associated Press reported. The original vaccines still offer good prot...
marketwatch.com · 2h ago
After Pfizer, Moderna Kickstarts Omicron-Targeted COVID-19 Vaccine Trial
Moderna Inc (NASDAQ: MRNA) has started a mid-stage study, testing a booster dose of its COVID-19 vaccine specifically 
Benzinga · 2h ago
Two-thirds of Omicron COVID cases are reinfections: English study
A new study has found that a vast majority of people recently infected with Omicron variant say they had already had Covid previously - CNBC. Imperial College London’s React study
Seekingalpha · 6h ago
UPDATE 1-Moderna starts trial testing Omicron-specific booster shot
Moderna Inc said on Wednesday it had dosed the first participant in a mid-stage study testing a booster shot of its vaccine specifically tailored to the fast-spreading Omicron COVID-19 variant. The company also reported data showing that neutralizing anti...
Reuters · 14h ago
Vaccine Doses Top 10 Billion; Long Covid Studied: Virus Update
(Bloomberg) -- More than 10 billion doses of Covid-19 vaccine have been administered across the globe, according to the latest tally from the Bloomberg Vaccine Tracker.Most Read from BloombergA Nor’easter Approaching New York Risks Becoming a Bomb CycloneP...
Bloomberg · 15h ago
Moderna starts trial testing Omicron-specific booster shot
reuters.com · 15h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNA. Analyze the recent business situations of Moderna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

10.00%Strong Buy
35.00%Buy
45.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRNA stock price target is 275.83 with a high estimate of 506.00 and a low estimate of 86.00.
High506.00
Average275.83
Low86.00
Current 154.96
EPS
Actual
Estimate
1.834.366.889.40
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 1.22K
Institutional Holdings: 247.04M
% Owned: 60.93%
Shares Outstanding: 405.45M
TypeInstitutionsShares
Increased
382
37.49M
New
311
3.74M
Decreased
320
25.95M
Sold Out
72
949.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.76%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
General Counsel/Secretary
Lori Henderson
Other
Marcello Damiani
Other
Ray Jordan
Other
Corinne Le Goff
Other
Jose Vega
Other
Tal Zvi Zaks
Secretary
Shannon Klinger
Independent Director
Stephen Berenson
Independent Director
Sandra Horning
Independent Director
Robert Langer
Independent Director
Elizabeth Nabel
Independent Director
Francois Nader
Independent Director
Paul Sagan
Independent Director
Elizabeth Tallett
No Data
About MRNA
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.